Phio Pharmaceuticals Corp. (PHIO) - Form 8-K Summary
Business Context and Reporting Period
Phio Pharmaceuticals Corp. filed a Current Report on Form 8-K on August 6, 2026, to announce its financial results for the quarterly period ended June 30, 2026. The company is incorporated in Delaware and trades on The Nasdaq Capital Market under the symbol PHIO.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The report serves as a notification that results have been released, with the detailed data contained in the attached press release (Exhibit 99.1), which is not included in the provided text.
Material Changes
No material changes versus the prior comparable period are described in the filing text. The document references the results but does not summarize the variances or trends.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, specific risk factors, contingencies, or unusual items. It explicitly states that the information in Item 2.02 and the attached press release will not be treated as "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific Q2 2026 financial figures.
- Verify the company's cash position and runway given the lack of disclosed liquidity metrics in this summary.
- Confirm any updates to clinical trial progress or regulatory milestones mentioned in the full press release.
- Check for any new debt covenants or financing activities not detailed in this 8-K cover page.